RCE Recce Pharmaceuticals Ltd
—Mkt Cap: —P/E: —1d ago
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of …
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value64.36M USD
Revenue (TTM)6.54M USD
Gross Profit857.62K USD
Net Income (TTM)-10.34M USD
Revenue/Share0.03 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000RCE5
Valuation
P/E (Trailing)—
P/E (Forward)2.52
PEG—
EV/EBITDA-6.75
EV/Revenue9.84
P/S9.04
P/B-4.83
EPS (TTM)-0.05
EPS (Forward)0.11
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin13.11%
Oper. Margin20.43%
EBITDA Margin-145.73%
Profit Margin-158.06%
ROE89.47%
ROA-175.44%
Growth
Revenue Growth1509.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.84M USD
CapEx (TTM)42.82K USD
FCF Margin-16.35%
FCF Yield—
Net Debt5.19M USD
Net Debt/EBITDA-0.54
Balance Sheet
Debt/Equity-0.62
Current Ratio0.44
Quick Ratio0.40
Book Value/Sh-0.06 AUD
Cash/Share0.01 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)2.550 AUD
Target Range2.550 AUD – 2.550 AUD
# Analysts1
Ownership
Shares Out.305.77M
Float219.81M
Insiders40.67%
Institutions13.65%
Technical
SMA 500.3448 AUD
SMA 2000.4634 AUD
Beta0.54
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)119.17K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—